CRISPR Therapeutics AG
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.5M
- Net income
- -$581.6M
- Total assets
- $2.3B
- Market cap
- $5.1B
- Operating margin
- -18933.6%
- Net margin
- -16569.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.5M
- Operating expenses
- $668.1M
- Operating income
- -$664.6M
- Income tax
- $3.6M
- Net income
- -$581.6M
- EPS (basic)
- $-6.47
- EPS (diluted)
- $-6.47
Balance sheet
- Total assets
- $2.3B
- Current assets
- $2.0B
- Total liabilities
- $343.4M
- Current liabilities
- $149.1M
- Shareholders’ equity
- $1.9B
Cash flow
- Operating cash flow
- -$345.0M
- Investing cash flow
- -$31.8M
- Financing cash flow
- $426.0M
- Net cash flow
- $49.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.1B
- EPS (diluted)
- $-6.47
- Shares outstanding
- 103.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 19, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $581.6M in FY2025.
- Revenue declined 100% from FY2021 to FY2025.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CRISPR Therapeutics AG.
Write a review
News about CRISPR Therapeutics AG
News & sentiment via Polygon.io
